Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 448-449, 2008; 10.1373/clinchem.2007.097501
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Collinson, P.
Right arrow Articles by Laitinen, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Collinson, P.
Right arrow Articles by Laitinen, P. H.
(Clinical Chemistry. 2008;54:448-449.)
© 2008 American Association for Clinical Chemistry, Inc.

Letters to the Editor

How Well Do Laboratories Follow Guidelines on Cardiac Markers? The Cardiac Marker Guideline Uptake in Europe Study

Paul Collinson1, Kari Pulkki2, Janne Suvisaari2, Jan Ravkilde3, Ana Stavljenic-Rukavina4, Angelika Hammerer-Lercher5, Hannsjörg Baum6, Marja P. van Dieijen-Visser7 and Paivi H. Laitinen8,a

1 St George’s Hospital, London, UK
2 Helsinki University Hospital, Helsinki, Finland
3 Aarhus University Hospital (Aalborg), Aalborg, Denmark
4 University of Zagreb, Zagreb, Croatia
5 Innsbruck Medical University, Innsbruck, Austria
6 Kliniken Ludwigsburg-Bietigheim, Germany
7 University Hospital Maastricht, Maastricht, the Netherlands
8 Oulu University Hospital, Oulu, Finland

aAddress correspondence to this author at: Laboratory, Oulu University Hospital, PO Box 500, FIN-90029 OYS, Oulu, Finland, Fax: 358-8-3154474, e-mail paivi.h.laitinen@ppshp.fi

The first 20% of the full text of this article appears below.


To the Editor:

Evidence-based medicine is recognized as underlying good clinical practice. Similarly, evidence-based laboratory medicine should be used to guide and monitor laboratory testing. One area where laboratory testing has undergone a revolutionary change is in the diagnosis of acute coronary syndrome (ACS)1 , as underscored in the American College of Cardiology (ACC) and the European Society of Cardiology (ESC) consensus document on the definition of and diagnostic approach of myocardial infarction in 2000, updated in 2007. Since the original reports, the measurement of cTnT and cTnI has been recommended in many guidelines, (1)(2) and they have formed a part of the redefinition of myocardial infarction (3).

The CARdiac MArker Guideline Uptake in Europe study (CARMAGUE) was a pilot study to provide baseline data and validate a web-based audit tool to assess compliance of cardiac marker testing in current clinical practice. The study was sponsored by the European Federation . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.